Precision Gene Editing.
At Acrigen, we believe that gene editing will revolutionize medicine and bring hope to millions of patients suffering from genetic diseases. We are developing Precision Gene Editing Systems to harness the power of CRISPR for use in human therapeutics. Acrigen’s proprietary technology leverages novel αCas and μCas CRISPR gene editors coupled with ErAcrs (engineered anti-CRISPR proteins) to create an editing toolbox with best-in-class efficiency and precision. Our technology will expand the impact of CRISPR by improving the efficacy and safety of novel gene editing therapies.
High precision CRISPR systems expand the scope of human genome editing.
Acrigen Technology
Gene editing with αCas & μCas nuclease libraries.
Acrigen has discovered and engineered αCas and μCas, 2 families of novel CRISPR-Cas nucleases fine tuned for human gene editing. Using our Nuclease Discovery Engine, we identified libraries of unique CRISPR-Cas enzymes for use in human gene editing therapies. These novel editing systems are further engineered and optimized to enhance genome editing for in vivo and ex vivo applications.
Increased precision with ErAcr proteins.
To further increase the precision of our novel gene editing systems, we have developed ErAcr proteins - Engineered Recombinant Anti-CRISPR proteins. These small peptides eliminate off-target gene editing by selective inhibition of the CRISPR-Cas nuclease. The Cas:ErAcr pair forms the core of our precision gene editing system.
Let’s Work Together.
Contact us about licensing our CRISPR-Cas Nuclease Library and Precision Enhancing ErAcr Proteins.